Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study

Clinical Infectious Diseases

Volumn 61, Issue 12, 2015, Pages 1771-1777

  Dalfino, Lidia ^a   Puntillo, Filomena ^a   Ondok, Maria Josephine Mura ^a   Mosca, Adriana ^b   Monno, Rosa ^a   Coppolecchia, Sara ^a   Spada, Maria Luigia ^a   Bruno, Francesco ^a   Brienza, Nicola ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Department of Interdisciplinary Medicine ^*  (United States)

Author keywords

acute kidney injury; ascorbic acid; colistimethate sodium; colistin; critically ill

Indexed keywords

AMINOGLYCOSIDE; ASCORBIC ACID; CARBAPENEM DERIVATIVE; COLISTIN; CONTRAST MEDIUM; LOOP DIURETIC AGENT; RIFAMPICIN; VANCOMYCIN; ANTIDOTE; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; APACHE; ARTICLE; BLOODSTREAM INFECTION; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL PROTECTION; RISK ASSESSMENT; RISK REDUCTION; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ACUTE KIDNEY INJURY; ADOLESCENT; BLIGHIA; CHEMICALLY INDUCED; CRITICAL ILLNESS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MIDDLE AGED; RISK FACTOR; SEPSIS; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIDOTES; ASCORBIC ACID; BLIGHIA; COLISTIN; CRITICAL ILLNESS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; YOUNG ADULT;

EID: 84949602406     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ717     Document Type: Article

References (40)

1. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65:1984-90.
2. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2010; 55:3284-94.
3. Pogue JM, Lee J, Marchaim D, et al. Incidence and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-84.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney InjuryWork Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2:124-38.
5. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724-8.
6. Kwon J-A, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Ag 2010; 35:473-7.
7. Sorlì L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study. BMC Infect Dis 2013; 13:380-8.
8. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacother 2013; 33:812-6.
9. Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methasulphonate sodium. Int J Antimicrob Agents 2014; 43:349-52.
10. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014; 58:2740-6.
11. Phe K, Johnson MJ, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother 2014; 58:6946-8.
12. Doshi N, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacother 2011; 31:1257-64.
13. Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Crit Care 2013; 17:R174.
14. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee. Definition for sepsis and organ failures and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
15. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17-60.
16. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation ofMICs and zone diameters. Version 5.0; 2015. Available at: http://www.eucast.org/clinical-breakpoints/. Accessed 28 August 2015.
17. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
18. Niederman MS, Craven DE, Bonten MJ, et al. American Thoracic Society and the Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005; 171:388-416.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Int Med 2009; 150:604-12.
20. Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol 2002; 22:320-4.
21. Gauthier T, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392-6.
22. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013; 57:1300-3.
23. DeRyke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54:4503-5.
24. Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2015; 46:678-85.
25. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? Clin Infect Dis 2012; 54:1720-6.
26. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56:398-404.
27. Robert JA, Lipman J. Closing the loop-A colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin Infect Dis 2012; 54:1727-9.
28. Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. Association between colistin dose and development of nephrotoxicity. Crit Care Med 2015; 43:1187-93.
29. Ozyilmaz E, Ebinc FA, Gulbahar O, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 2011; 37:141-6.
30. Yousef J, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011; 55:4044-9.
31. Ghlissi Z, Hakim A, Mnif H, et al. Evaluation of colistin nephrotoxicity administered at different doses in the rat model. Ren Fail 2013; 35:1130-5.
32. Ozkan G, Ulusoy S, Orem A, et al. How does colistin-induced nephropathy develop and can it be treated? Antimicrob Ag Chemother 2013; 57:3463-9.
33. Dai C, Li J, Tang S, Li J, Xiao X. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 2014; 58:4075-85.
34. Dai C, Tang S, Deng S, et al. Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway. Antimicrob Agents Chemother 2015; 59:579-85.
35. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012; 67:452-9.
36. Doise JM, Aho LS, Quenot JP, et al. Plasma antioxidant status in septic critically ill patients: A decrease over time. Fundam Clin Pharmacol 2008; 22:203-9.
37. Fowler AA III, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J TranslMed 2014; 12:32.
38. Oudemans-van Straaten HM, Spoelstra AME, Waard MC. Vitamin C revisited. Crit Care 2014; 18:460.
39. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
40. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, Nation R, Li J, Thamlikitkul V. Effect of ascorbic acid on colistin-associated nephrotoxicity: A preliminary clinical study. Antimicrob Agents Chemother 2015; 59:3224-32.